For Q1 FY2020 (ended March 31, 2020), Larimar reported no revenue and a net loss of $29.6 million, compared to a net loss of $13.9 million in the prior year period. Operating loss was $31.1 million, and diluted EPS was -$0.61. Long-term debt stood at $14.5 million as of December 31, 2019.
•Revenue was $0 for Q1 FY2020.
•Net loss widened to $29.6 million from $13.9 million year-over-year.
•Operating loss was $31.1 million.
•Diluted EPS was -$0.61.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The company leverages its novel cell penetrating peptide technology platform to create therapies. Its lead product candidate is CTI-1601, which is currently in a Phase 2 open-label extension (OLE) clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disorder. The company is dedicated to addressing unmet medical needs in rare disease areas, with a primary focus on advancing CTI-1601 through clinical development.
Where is Larimar Therapeutics (LRMR) listed and what currency does it trade in?
Larimar Therapeutics, Inc. is listed on the NasdaqGM exchange under the ticker symbol LRMR. The company's shares are traded in US Dollars (USD). As a US-based company, it is part of the Nasdaq Global Market, which is a tier of the Nasdaq stock exchange that lists companies meeting certain financial and liquidity requirements. Investors can buy and sell LRMR shares during regular trading hours on Nasdaq.
What sector and industry does Larimar Therapeutics (LRMR) belong to?
Larimar Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on using biological processes and technologies to develop drugs and therapies. The company's work is centered on rare diseases, which falls under the broader biotech umbrella. Biotechnology companies like Larimar often engage in research and development, clinical trials, and regulatory processes to bring new treatments to market.
Where is Larimar Therapeutics headquartered?
Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania, United States. This location serves as the company's corporate headquarters. Bala Cynwyd is a suburb of Philadelphia, placing the company in a region with a strong life sciences presence. The company primarily serves the US market, as its clinical trials and regulatory activities are focused within the United States. Being headquartered in the US allows Larimar to closely collaborate with research institutions and regulatory bodies like the FDA.